Efficacy News and Research

RSS

TVA Medical announces results from multicenter clinical study of everlinQ endoAVF System

TVA Medical, Inc., announced clinical trial results from a prospective, multicenter clinical study evaluating the everlinQ endoAVF System. This innovative medical technology creates hemodialysis access using vascular sites not traditionally used by surgeons for people with end-stage kidney disease (ESKD).

21 Nov 2015

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy.

21 Nov 2015

Atypical antipsychotic shows bipolar I depression efficacy

The atypical antipsychotic cariprazine may be effective for the treatment of bipolar I depression, phase II study findings show.

20 Nov 2015

12 months of liquid formula HIV drugs protect breastfeeding babies against HIV infection

A study from four countries in Africa, published in The Lancet, shows that providing babies with up to 12 months of liquid formula HIV drugs, while breastfeeding with their HIV-positive mothers, is highly effective at protecting them from infection, including in the 6–12 month period after birth which has not been analysed in previous research.

20 Nov 2015

Urine-derived iPSCs model could help predict patient response to cholesterol-lowering drugs

We all know how important it is to keep our levels of blood cholesterol - especially the 'bad' variety - in check with a healthy diet and regular exercise. Although cholesterol is a key structural component of cell membranes and is vital for the biosynthesis of certain hormones and vitamins, high levels can lead to the formation of arterial plaques, which are a major risk factor for coronary heart disease.

20 Nov 2015

Global tissue engineered medical devices market expected to cross US$ 26 billion by 2020

According to recently published Pharmaion report, "Global Tissue Engineered Medical Devices Market Forecast & Opportunities, 2020", global tissue engineered medical devices market is anticipated to cross US$ 26 billion by 2020.

19 Nov 2015

VolitionRx's NuQ blood tests accurately detect more than 90% of lung cancer cases

VolitionRx Limited today announced interim data demonstrating its NuQ blood tests have accurately detected more than 90% of lung cancer cases in a study of 73 patients.

19 Nov 2015

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

FDA approves Narcan nasal spray to prevent or reverse effects of opioid overdose

Today the U.S. Food and Drug Administration approved Narcan nasal spray, the first FDA-approved nasal spray version of naloxone hydrochloride, a life-saving medication that can stop or reverse the effects of an opioid overdose. Opioids are a class of drugs that include prescription medications such as oxycodone, hydrocodone, and morphine, as well as the illegal drug heroin.

18 Nov 2015

Study examines association between IV products and anaphylaxis risk

Cunlin Wang, M.D., Ph.D., of the U.S. Food and Drug Administration, Silver Spring, Md., and colleagues studied recipients of intravenous (IV) iron (n = 688,183) enrolled in the fee-for-service Medicare program from January 2003 to December 2013.

18 Nov 2015

MicroRNA reduces tumor growth, increases cell death in castration-resistant prostate cancer

Researchers at the UC Davis Comprehensive Cancer Center have shown that the microRNA, miR-124, reduced tumor growth and increased cell death in castration-resistant prostate cancer.

17 Nov 2015

Vitamin E shows same efficacy in diabetic and nondiabetic patients

There have been numerous studies on the safety and efficacy of using vitamin E to treat nondiabetic patients with nonalcoholic steatohepatitis (NASH), but researchers at the annual meeting of the American Association for the Study of Liver Diseases presented results of vitamin E in diabetic and nondiabetic patients.

17 Nov 2015

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease.

17 Nov 2015

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).

17 Nov 2015

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

17 Nov 2015

Positive data from AbbVie's HCV clinical development program presented at The Liver Meeting of AASLD

AbbVie, a global biopharmaceutical company, today announced data from the SURVEYOR studies of its investigational HCV regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, that show high rates of sustained virologic response at 12 weeks post-treatment (SVR 12) in non-cirrhotic patients with chronic hepatitis C virus (HCV) infection.

17 Nov 2015

Birmingham researchers identify how Salmonella infections can lead to life-threatening thrombosis

Researchers from the University of Birmingham have, for the first time, identified how Salmonella infections that have spread to our blood and organs can lead to life-threatening thrombosis.

17 Nov 2015

Drug prevents onset of cognitive and cellular effects in mouse model of Alzheimer’s disease

In a novel animal study design that mimicked human clinical trials, researchers at University of California, San Diego School of Medicine report that long-term treatment using a small molecule drug that reduces activity of the brain's stress circuitry significantly reduces Alzheimer's disease (AD) neuropathology and prevents onset of cognitive impairment in a mouse model of the neurodegenerative condition.

17 Nov 2015

FDA grants accelerated approval for Darzalex to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma.

17 Nov 2015

MIPT researchers patent graphene biosensors that may accelerate development of novel drugs

The US Patent Office has recently published the patent application (no. US 2015/0301039), which was filed by the MIPT in May this year and is titled Biological Sensor and a Method of the Production of Biological Sensor. In Russia, this development is already protected by the patent No. 2527699 with a priority date of February 20, 2013. The key feature of the sensor is the use of a linking layer for biomolecule immobilization comprising a thin film of graphene or graphene oxide.

17 Nov 2015

Efficacy News and Research

TVA Medical announces results from multicenter clinical study of everlinQ endoAVF System

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Atypical antipsychotic shows bipolar I depression efficacy

12 months of liquid formula HIV drugs protect breastfeeding babies against HIV infection

Urine-derived iPSCs model could help predict patient response to cholesterol-lowering drugs

Global tissue engineered medical devices market expected to cross US$ 26 billion by 2020

VolitionRx's NuQ blood tests accurately detect more than 90% of lung cancer cases

Lilly, Merck expand oncology clinical trial collaboration

FDA approves Narcan nasal spray to prevent or reverse effects of opioid overdose

Study examines association between IV products and anaphylaxis risk

MicroRNA reduces tumor growth, increases cell death in castration-resistant prostate cancer

Vitamin E shows same efficacy in diabetic and nondiabetic patients

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

Positive data from AbbVie's HCV clinical development program presented at The Liver Meeting of AASLD

Birmingham researchers identify how Salmonella infections can lead to life-threatening thrombosis

Drug prevents onset of cognitive and cellular effects in mouse model of Alzheimer’s disease

FDA grants accelerated approval for Darzalex to treat patients with multiple myeloma

MIPT researchers patent graphene biosensors that may accelerate development of novel drugs

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News